搜尋
Eli Lilly and Co
LLY添加自選
1208.120USD
+79.000+7.01%
收盤 06/26, 16:00（美東）報價延遲15分鐘
1.14T總市值
42.84本益比TTM
關於 Eli Lilly and Co 公司
禮來公司是一家制藥公司。該公司在人類藥品領域發現、開發、製造和銷售產品。其糖尿病、肥胖症和其他心臟代謝產品包括 Basaglar、Humalog、Mounjaro、Trulicity 和 Zepbound。其腫瘤產品包括 Alimta、Retevmo、Tyvyt 和 Verzenio。其免疫學產品包括 Ebglyss、Olumiant、Omvoh 和 Taltz。其神經科學產品包括 Cymbalta 和 Emgality。其其他產品和療法包括 Cialis 和 Forteo。該公司通過位於美國（包括波多黎各）以及歐洲和亞洲的工廠生產和分銷其產品。該公司通過其子公司 POINT Biopharma Global Inc. 從事放射性藥物的發現、開發和製造，以及臨牀和臨牀前放射性配體療法。該公司還在開發用於治療炎症性腸病 (IBD) 的 α4β7 整合素口服小分子抑制劑 (稱爲 MORF-057)。
Eli Lilly and Co簡介
公司代碼LLY
公司名稱Eli Lilly and Co
上市日期Jul 09, 1970
CEORicks (David A)
員工數量47000
證券類型Ordinary Share
年結日Jul 09
公司地址Lilly Corporate Ctr
城市INDIANAPOLIS
上市交易所NASDAQ OMX NASDAQ Basic NYSE
國家United States of America
郵編46285
電話13172762000
網址https://www.lilly.com/
公司代碼LLY
上市日期Jul 09, 1970
CEORicks (David A)
Eli Lilly and Co公司高管
名稱
名稱/職務
職務
持股
持股變動
Ms. Anne E. White
Ms. Anne E. White
Executive Vice President, President - Lilly Neuroscience
Executive Vice President, President - Lilly Neuroscience
74.21K
+11.64%
Mr. Patrik Jonsson
Mr. Patrik Jonsson
Executive Vice President, President of Lilly Cardiometabolic Health and President, Lilly USA
Executive Vice President, President of Lilly Cardiometabolic Health and President, Lilly USA
61.12K
+11.45%
Ms. Anat Hakim
Ms. Anat Hakim
Executive Vice President, General Counsel, Secretary
Executive Vice President, General Counsel, Secretary
55.56K
+53.81%
Mr. Edgardo Hernandez
Mr. Edgardo Hernandez
Executive Vice President, President - Manufacturing Operations
Executive Vice President, President - Manufacturing Operations
46.10K
+13.81%
Mr. Ilya Yuffa
Mr. Ilya Yuffa
Executive Vice President, President of Lilly International
Executive Vice President, President of Lilly International
29.80K
-8.39%
Mr. Diogo Rau
Mr. Diogo Rau
Executive Vice President, Chief Information and Digital Officer
Executive Vice President, Chief Information and Digital Officer
26.40K
+25.30%
Dr. Katherine Baicker, Ph.D.
Dr. Katherine Baicker, Ph.D.
Independent Director
Independent Director
23.54K
+0.70%
Mr. Lucas E. Montarce
Mr. Lucas E. Montarce
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
16.26K
+9.66%
Mr. Eric Dozier
Mr. Eric Dozier
Executive Vice President, Chief People Officer
Executive Vice President, Chief People Officer
14.46K
+31.93%
Ms. Kimberly H. Johnson
Ms. Kimberly H. Johnson
Independent Director
Independent Director
3.27K
+0.67%
查看更多
名稱
名稱/職務
職務
持股
持股變動
Ms. Anne E. White
Ms. Anne E. White
Executive Vice President, President - Lilly Neuroscience
Executive Vice President, President - Lilly Neuroscience
74.21K
+11.64%
Mr. Patrik Jonsson
Mr. Patrik Jonsson
Executive Vice President, President of Lilly Cardiometabolic Health and President, Lilly USA
Executive Vice President, President of Lilly Cardiometabolic Health and President, Lilly USA
61.12K
+11.45%
Ms. Anat Hakim
Ms. Anat Hakim
Executive Vice President, General Counsel, Secretary
Executive Vice President, General Counsel, Secretary
55.56K
+53.81%
Mr. Edgardo Hernandez
Mr. Edgardo Hernandez
Executive Vice President, President - Manufacturing Operations
Executive Vice President, President - Manufacturing Operations
46.10K
+13.81%
Mr. Ilya Yuffa
Mr. Ilya Yuffa
Executive Vice President, President of Lilly International
Executive Vice President, President of Lilly International
29.80K
-8.39%
Mr. Diogo Rau
Mr. Diogo Rau
Executive Vice President, Chief Information and Digital Officer
Executive Vice President, Chief Information and Digital Officer
26.40K
+25.30%
常見問題
Eli Lilly and Co的前五大股東是誰？
Eli Lilly and Co的前五大股東如下：Ms. Anne E. White
有多少機構持有Eli Lilly and Co(LLY)的股份？
截至2026Q1，共有6331家機構持有Eli Lilly and Co的股份，合計持有的股份價值約為864.16M，占公司總股份的91.72% 。與2025Q4相比，機構持股有所增加，增幅為69007266.00。
哪個業務部門對Eli Lilly and Co的收入貢獻最大？
在2026Q1，Diabetes-Mounjaro業務部門對Eli Lilly and Co的收入貢獻最大，創收6.52B，占總收入的37.02% 。
